WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (NASDAQ:EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, David Riggs, Chief Financial Officer, and other members of Eagle's senior management team will host an Investor Day in New York City on November 11, 2016.
The event will focus on the Company's growth initiatives, R&D pipeline and financial outlook. It will provide additional insight on Ryanodex® for Exertional Heat Stroke and Methamphetamine and Ecstasy Intoxication, recent product launches and new growth opportunities.
Event: Eagle Pharmaceuticals Investor Day
Date: November 11, 2016
Time: 8:00 a.m. ET to 11:30 a.m. ET (registration and breakfast begin at 7:00 a.m. ET).
Location: The Pierre 2 East 61st Street, New York City
Institutional investors and analysts who wish to register can RSVP to Lisa Wilson, Investor Relations for Eagle Pharmaceuticals, either via telephone at 1-212-452-2793 or e-mail at email@example.com.
An audio webcast of the presentation will be available by visiting the Investor Relations section of Eagle Pharmaceuticals web site at www.eagleus.com. A replay of the presentation will be available for 90 days.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.